Phase 1 Heart Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been clinically diagnosed with heart failure
- People whose doctors have no plans to change or adjust their heart failure medications or devices during the study period
- People who have not had an unplanned hospital stay in the past 2 weeks
- People whose fluid levels are considered stable and well-managed by their medical team
- People whose blood potassium level is 5.0 mmol/L or below
- People whose blood sodium level is 130 mEq/L or above
- People who are older than 18 years of age
- People whose haemoglobin (a measure of red blood cells) is 8 g/dL or above
- People whose test results show that their body is not responding well enough to a standard water tablet (diuretic) challenge, based on specific measurements of sodium in the urine and other kidney function indicators (confirm with trial site)
Who may not be able to join:
- People whose kidneys are functioning at a very low level (confirm with trial site) or who are on dialysis or another form of kidney replacement therapy
- People who have taken certain types of water tablets (non-loop diuretics) in the last 7 days or so, with some exceptions for low-dose medications — the trial site can clarify which medications are affected
- People with a history of sudden severe fluid build-up in the lungs requiring hospitalisation and breathing support, or people with a heart condition that makes their fluid balance particularly fragile, such as amyloid cardiomyopathy
- People whose haemoglobin is below 8 g/dL or who have anaemia causing symptoms
- People who are pregnant or breastfeeding
- People who are unable to provide written informed consent or who would have difficulty following the study's procedures and appointments
- People who have a chronic urinary retention condition that would make timed urine collection difficult
- People currently taking lithium
- People currently taking pimozide or thioridazine
- People who have been diagnosed with liver failure
- People who have an allergy or medical reason to avoid sulfonamide-type medications
- People who have an allergy or medical reason to avoid thiazide diuretics or the specific medication bendroflumethiazide
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jeffrey Testani, Yale University
Phone: 203-737-3571
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in peak FENa from bumetanide monotherapy to bumetanide plus combination therapy; Change in distal sodium reabsorption; Correlation between distal sodium reabsorption and uEV pendrin/CD9
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.